Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C6-NH2 serves as an E3 ligase ligand-linker conjugate, featuring a thalidomide-based cereblon ligand with an integrated linker. This compound is utilized in the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation pathways. Its unique structure allows for selective degradation of specific proteins, making it valuable in cancer research and other therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that integrates a Thalidomide-derived cereblon ligand with a PEG4 linker, facilitating the targeted degradation of proteins via PROTAC technology. This compound enables selective modulation of protein levels in cellular systems, making it a valuable tool for drug development and research into targeted protein degradation mechanisms. Its applications extend to studying E3 ligase interactions and enhancing the effectiveness of therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-O-C8-NH2 is an E3 ligase ligand-linker conjugate integrating a Thalidomide-derived cereblon ligand with a C8 linker, designed for use in PROTAC (proteolysis-targeting chimera) applications. This compound facilitates targeted protein degradation by harnessing the ubiquitin-proteasome system, thereby enabling the selective modulation of protein levels within cellular environments. Its primary applications lie in the development of novel therapeutics and research in cellular pathways regulated by ubiquitination. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C3-acid is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a component of the E3 ubiquitin ligase complex. This compound is utilized in PROTAC (Proteolysis Targeting Chimeras) technology to facilitate targeted degradation of proteins, enhancing the study of protein homeostasis and therapeutic interventions in various diseases. Its unique structure allows for the development of novel bioconjugates for offsetting pathological protein accumulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a hexylamine linker. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, facilitating targeted protein degradation by engaging specific E3 ligases. Thalidomide-NH-C6-NH2 is primarily utilized in research applications aimed at studying protein turnover and modulating cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-Piperidine is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a key component in the ubiquitin-proteasome system. This compound incorporates a Thalidomide-based ligand and a piperazine-piperidine linker, making it suitable for use in PROTAC (proteolysis-targeting chimeras) technology. Its design facilitates targeted degradation of specific proteins, providing valuable insight into protein regulation and function in various biological contexts. Thalidomide-Piperazine-Piperidine is ideal for research applications involving targeted protein degradation and cellular signaling pathways. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-PEG2-C2-NH2 serves as an E3 ligase ligand-linker conjugate, playing a critical role in the modulation of immune responses. This compound exhibits immunomodulatory activity, making it relevant for cancer research and therapeutic applications. Its unique design allows for specific targeting of E3 ligases, facilitating the study of protein degradation pathways in cancer biology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amide-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that features thalidomide as a cereblon ligand, combined with a five-carbon amine linker. This compound is designed for applications in Proteolysis Targeting Chimeras (PROTAC) technology, facilitating targeted protein degradation. Its mechanism involves the binding of the conjugate to E3 ligases, enabling the selective degradation of target proteins, which is useful in drug discovery and development for various therapeutic applications. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-C2-PEG3-OH is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand paired with a polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeric) strategies, specifically for the degradation of BCL-XL through targeted ubiquitination. Its capabilities enable precise modulation of protein levels, facilitating research in targeted protein degradation and its applications in cancer therapy. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C4-NH-Boc is an E3 ligase ligand-linker conjugate, featuring a cereblon ligand derived from Thalidomide and a specialized linker designed for PROTAC technology. This compound facilitates the targeted degradation of proteins by harnessing the ubiquitin-proteasome system, making it a valuable tool for researchers investigating protein turnover and cellular regulation. Its applications extend to drug discovery, developmental biology, and therapeutics, where selective protein modulation is critical. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine-O-azetidine-boc is a conjugate designed as an E3 ubiquitin ligase ligand-linker. This compound facilitates the synthesis of complete PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation in various biological research applications. It serves as a valuable tool for studying protein function and modulation, particularly in therapeutic contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C2-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a designated linker for use in PROTAC technology. This compound is designed to facilitate targeted protein degradation by harnessing the cellular ubiquitin-proteasome system. Its applications extend to studies in drug discovery and cellular signaling, enabling researchers to investigate the modulation of protein levels with precision. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-C-PIP-C-boc is an E3 ligase ligand-linker conjugate that incorporates Thalidomide, serving as a recruiter for the cereblon (CRBN) protein. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by acting as a critical intermediate for the synthesis of complete PROTAC molecules. Its utility in research includes applications in targeted protein degradation strategies, providing a platform for innovative therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C3-NH2 is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from Thalidomide with a specialized linker for PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates targeted protein degradation by recruiting specific substrates to the ubiquitin-proteasome system. Thalidomide-O-C3-NH2 is instrumental for research applications in protein regulation and therapeutic development, particularly in understanding cellular processes and disease mechanisms. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-PEG4-NHS ester is a PEG-based linker designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). It functions as a ligand for E3 ligases, facilitating targeted protein degradation. This compound is instrumental in chemical biology research aimed at exploring pathways involved in protein turnover and has applications in developing therapeutics for diseases driven by dysregulated protein levels. -
E3 Ligase Ligand-Linker Conjugate
Biotin-Thalidomide is a biotinylated derivative of Thalidomide designed to selectively bind to the cereblon (CRBN) E3 ubiquitin ligase. This compound serves as a crucial ligand-linker conjugate for the development of proteolysis-targeting chimeras (PROTACs). Biotin-Thalidomide facilitates targeted proteasomal degradation of specific proteins, making it a valuable tool for research in targeted protein degradation and molecular biology. Its utility extends to applications in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand combined with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in proteolysis-targeting chimera (PROTAC) applications, facilitating targeted protein degradation by promoting the interaction between the target protein and the E3 ubiquitin ligase. Its unique structure enables researchers to explore novel therapeutic strategies in cellular and molecular biology studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-azide is an E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. It serves as an essential component in PROTAC technology, facilitating targeted protein degradation. This compound is a versatile click chemistry reagent, containing an azide group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN moieties. These properties make it valuable for various bioconjugation applications in chemical biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine 5-fluoride is a synthesized compound that functions as an E3 ligase ligand-linker conjugate, featuring the Thalidomide-derived cereblon ligand. This reagent is designed for applications in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. Its unique structure allows for effective modulation of protein levels in experimental settings, making it a valuable tool in the study of cellular processes and therapeutic development. -
E3 ligase ligand-linker conjugate
Thalidomide-4-O-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that plays a critical role in the targeted protein degradation (PROTAC) system, specifically in dTAG-13 applications. This compound is utilized for its ability to degrade FKBP12F36V and bromodomain and extraterminal (BET) proteins, facilitating the modulation of various cellular processes. Its utility in research allows for advancements in understanding protein function and the development of therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG3-propionic acid is an E3 ligase ligand-linker conjugate that combines the thalidomide-derived cereblon ligand with a three-unit polyethylene glycol (PEG) linker. This compound is utilized in PROTAC technology to facilitate targeted protein degradation by engaging E3 ligases. Its design enables efficient delivery of the cereblon ligand to specific cellular targets, making it valuable for research in protein homeostasis and therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate designed to facilitate the synthesis of dCBP-1. This compound acts as a potent and selective heterobifunctional degrader targeting the p300/CBP proteins, enabling targeted protein degradation for research applications in cellular processes, epigenetics, and cancer biology. Researchers can utilize this conjugate to explore pathways and mechanisms regulated by p300/CBP, advancing the understanding of transcriptional regulation and related therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C6-COOH is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a carbon chain linker, facilitating the development of PROTAC (Proteolysis Targeting Chimera) molecules. This compound engages the cereblon protein, effectively modulating protein degradation pathways. Thalidomide-O-C6-COOH is suitable for research applications focused on targeted protein degradation and exploring the therapeutic potential of PROTAC-based strategies in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that utilizes the Thalidomide-based cereblon ligand in conjunction with a specialized linker designed for PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates targeted protein degradation, enabling the selective modulation of protein levels within cells. It is valuable for researchers investigating protein homeostasis, targeted therapy mechanisms, and the development of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a substrate receptor in the CRL4 ubiquitin-proteasome system. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs), offering a novel approach for selective protein degradation in various biological research applications. Its unique structure allows for the effective modulation of protein levels, making it a valuable tool in cellular biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a specialized linker utilized in PROTAC technology. This compound facilitates selective protein degradation by engaging the E3 ubiquitin ligase pathway, making it a valuable tool for investigating targeted protein modulation and therapeutic applications in cancer research and other diseases. Its structural design enhances its potential in developing targeted protein degradation strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C10-COOH is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived CRBN ligand. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, enabling selective degradation of target proteins. Its biological activity is critical for research applications focused on targeted protein degradation and cellular modulation in various therapeutic contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-C2-amido-C2-COOH is a ligand-linker conjugate targeting the CRBN E3 ubiquitin ligase. This compound is designed for the development of proteolysis-targeting chimeras (PROTACs), specifically facilitating the degradation of CDK2/9. It serves as a valuable tool in research focused on protein degradation pathways and the modulation of cellular processes through targeted protein elimination. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand integrated with a flexible linker tailored for PROTAC (Proteolysis Targeting Chimera) applications. This compound demonstrates the capacity to facilitate targeted protein degradation by recruiting E3 ligases to specific substrates, thereby enhancing the control of protein levels in cellular systems. It is valuable for research in targeted therapy and protein regulation studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-NH-PEG1-COOH TFA functions as an E3 Ligase Ligand-Linker Conjugate that targets Cereblon (CRBN). This compound selectively recruits the CRBN protein, facilitating targeted protein degradation pathways. Thalidomide-4-NH-PEG1-COOH TFA is a critical intermediate in the synthesis of CRBN-based PROTAC molecules, making it valuable for research into novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG1-C2-NH2 is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound features a Thalidomide-derived cereblon ligand that facilitates the recruitment of specific substrates to the ubiquitin-proteasome system. Its linker component is compatible with PROTAC technology, making it a valuable tool for researchers investigating therapeutic strategies aimed at modulating protein levels within cells. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C8-NH2 is a synthetic E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand. This compound serves as a valuable tool in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted degradation of specific proteins in cellular systems. It is widely utilized in studies focusing on protein homeostasis, disease modeling, and therapeutic development in various fields including cancer research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a C8 amido linker. This compound is specifically designed for use in PROTAC technology, facilitating targeted protein degradation by recruiting E3 ligases to specific substrates. Its biochemical properties make it suitable for investigating protein modulation and therapeutic applications in cellular research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG2-C2-NH2 is a conjugate designed for E3 ligase targeting, featuring a Thalidomide-derived cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation by engaging E3 ligases through PROTAC technology. It is suitable for research applications aimed at exploring protein regulation and therapeutic interventions in various diseases. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG1-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker, designed for proteolysis-targeting chimera (PROTAC) applications. This compound facilitates the recruitment of E3 ligases, enabling targeted degradation of specific proteins within cellular environments. It is instrumental in the development of novel therapeutic strategies for modulating protein levels in research studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-Boc is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG4 linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. It exhibits key biological activity by modulating the E3 ligase pathways, making it a valuable tool in the study of protein homeostasis and therapeutic applications in disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amide-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon via its Thalidomide component. This compound is designed for use in PROTAC (proteolysis-targeting chimeras) technology, facilitating the targeted degradation of specific proteins within various biological pathways. Its application in chemical research allows for enhanced studies in protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C2-NH2 is a synthetic E3 ligase ligand-linker conjugate designed to target cereblon, a substrate receptor for the ubiquitin-proteasome system. This compound plays a crucial role in PROTAC technology, facilitating targeted protein degradation by linking a specific protein of interest to the E3 ligase for ubiquitination. Its application enhances the study of protein function and regulation in cellular processes, making it valuable for research in drug development and disease modulation. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG1-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate designed to target cereblon, a substrate receptor for the E3 ubiquitin ligase complex. This compound facilitates the development of PROTAC (proteolysis-targeting chimera) technology, enabling targeted protein degradation in various biological research applications. Its unique structure is instrumental in studying protein interactions and modulation within cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG3-C2-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a cereblon ligand derived from Thalidomide, coupled with a PEG3 linker, facilitating the development of proteolysis-targeting chimeras (PROTACs). Its primary utility lies in modulating protein levels within cellular systems, enabling researchers to investigate protein function and potential therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that targets cereblon through its Thalidomide-derived component. This compound is designed for applications in PROTAC technology, facilitating targeted protein degradation. Its structure combines a specific ligand with a functional linker, making it a valuable tool for research in cellular signaling and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG8-Ts is a synthesized E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with an eight-unit polyethylene glycol (PEG) linker. This compound is essential in the development of PROTAC (Proteolysis Targeting Chimeras) technology, enabling targeted degradation of specific proteins through the recruitment of E3 ligases. Its applications include research in targeted protein degradation, with potential implications in various therapeutic areas, including cancer and neurodegenerative diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine TFA is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG4 linker for use in proteolysis-targeting chimera (PROTAC) applications. This compound facilitates targeted protein degradation by promoting the interaction between E3 ligases and specific substrate proteins. It serves as a valuable tool for researchers investigating cellular protein regulation and therapeutic interventions in various disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to incorporate a thalidomide-based cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through PROTAC technology, enhancing specificity and efficacy in research applications. It serves as a valuable tool for studying the role of E3 ligases in cellular processes and for developing novel therapeutic strategies through targeted modulation of protein levels. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand. This reagent plays a crucial role in PROTAC (proteolysis-targeting chimeras) technology, facilitating targeted protein degradation. It is of significant interest in drug discovery and development research, particularly for studies aimed at modulating protein function and enhancing therapeutic efficacy. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C4-NH2 is an E3 ligase ligand-linker conjugate featuring a cereblon ligand derived from thalidomide, combined with a linker utilized in PROTAC technology. This compound is designed to selectively recruit E3 ligases for targeted protein degradation, making it valuable for studies in targeted therapy and drug development. It facilitates the exploration of protein dynamics and functions, contributing to advancements in cancer research and other diseases linked to protein misregulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enabling researchers to study protein interactions and dysregulation in various biological contexts. Its unique structure supports the development of novel therapeutic strategies by harnessing the ubiquitin-proteasome system for selective protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C5-NH2 is an E3 ligase ligand-linker conjugate that utilizes the cereblon ligand derived from Thalidomide, combined with a linker suitable for targeted protein degradation applications. This compound facilitates the design of PROTAC molecules, enabling the selective degradation of target proteins via the ubiquitin-proteasome pathway. Its function in research may enhance studies related to therapeutic modalities in cancer and other diseases through targeted protein regulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, an E3 ubiquitin ligase. This compound is designed for use in PROTAC technology, enabling targeted protein degradation and facilitating the selective modulation of protein levels in cellular systems. It is suitable for research applications focused on protein homeostasis and therapeutic development for various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C3-NH2 is an E3 ligase ligand-linker conjugate that integrates a thalidomide-derived cereblon ligand with a flexible linker designed for use in PROTAC (proteolysis-targeting chimera) technology. This compound facilitates the targeted ubiquitination and subsequent degradation of specific proteins, thereby allowing researchers to investigate protein function and regulation. Its applications extend to drug discovery and development, particularly in therapies targeting diseases driven by protein misfolding or dysregulation.
